Clinical Trial

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.
Protocol Amendment History 1123 amendments
This ClinicalTrials.gov record has been amended 1123 times since 2009-02-12; most recent amendment 2026-05-28.
Status change: Recruiting → Active, Not Recruiting 2016-05-16
Status change: Suspended → Recruiting 2013-10-07
Status change: Recruiting → Suspended 2013-01-21
Status change: Terminated → Recruiting 2011-03-11
Status change: Suspended → Terminated 2010-11-04
Status change: Recruiting → Suspended 2010-09-25
Status change: Not Yet Recruiting → Recruiting 2010-03-24
Status change: Recruiting → Not Yet Recruiting 2010-03-19
Status change: Not Yet Recruiting → Recruiting 2009-02-25
Trial Details
NCT Number NCT00843882
Lead Sponsor National Cancer Institute (NCI)
Conditions Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
Enrollment 247 participants
Start Date 2009-01-29
Primary Completion 2019-07-08 (estimated)
Study Completion 2026-10-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-29